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Abstract
Introduction: Mobility impairment is the leading cause of disability in the UK. Individuals with congenital mobility
impairments have unique experiences of health, quality of life and adaptation. Preference-based outcomes
measures are often used to help inform decisions about healthcare funding and prioritisation, however the
applicability and accuracy of these measures in the context of congenital mobility impairment is unclear. Inaccurate
outcome measures could potentially affect the care provided to these patient groups. The aim of this systematic
review was to examine the performance of preference-based outcome measures for the measurement of utility
values in various forms of congenital mobility impairment.
Methods: Ten databases were searched, including Science Direct, CINAHL and PubMed. Screening of reference lists
and hand-searching were also undertaken. Descriptive and narrative syntheses were conducted to combine and
analyse the various findings. Results were grouped by condition. Outcome measure performance indicators were
adapted from COSMIN guidance and were grouped into three broad categories: validity, responsiveness and
reliability. Screening, data extraction and quality appraisal were carried out by two independent reviewers.
Results: A total of 31 studies were considered eligible for inclusion in the systematic review. The vast majority of
studies related to either cerebral palsy, spina bifida or childhood hydrocephalus. Other relevant conditions included
muscular dystrophy, spinal muscular atrophy and congenital clubfoot. The most commonly used preference-based
outcome measure was the HUI3. Reporting of performance properties predominantly centred around construct
validity, through known group analyses and assessment of convergent validity between comparable measures and
different types of respondents. A small number of studies assessed responsiveness, but assessment of reliability was
not reported. Increased clinical severity appears to be associated with decreased utility outcomes in congenital
mobility impairment, particularly in terms of gross motor function in cerebral palsy and lesion level in spina bifida.
However, preference-based measures exhibit limited correlation with various other condition-specific and clinically
relevant outcome measures.
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Conclusion: Preference-based measures exhibit important issues and discrepancies relating to validity and
responsiveness in the context of congenital mobility impairment, thus care must be taken when utilising these
measures in conditions associated with congenital mobility impairments.
Keywords: Disability, Mobility impairment, Quality of life, Health-related quality of life, Patient reported outcomes,
Preference-based outcome measures, Utilities, QALYs
Introduction
Mobility impairment and assistive mobility technology
Mobility impairment is the leading cause of disability in
the UK, accounting for 52% of reported disabilities [1].
Mobility impairments arise from a vast array of different
disabilities, conditions, injuries and illnesses. However,
they can be classified broadly as either congenital (i.e.
from birth) or acquired (i.e. occurring later in life).
Whether a disability is present from birth or acquired
later on in life significantly influences individual adapta-
tion. For instance, individuals with congenital disabilities
exhibit higher degrees of life satisfaction, self-identity
and self-efficacy (related to their disability) than individ-
uals who have had to adapt to acquired disability [2].
Adaptation to disability is influenced by self-concept and
disability identity, which in turn are related to the onset
of disability [2].
Common congenital conditions which can impact mo-
bility include cerebral palsy (CP) and spina bifida (SB).
CP refers to a number of conditions caused by damage
to the parts of the brain which control movement, bal-
ance and posture, and can be caused either by abnormal
brain development or trauma. CP is symptomized by
varying degrees of permanent movement disorder, in-
cluding poor coordination, muscle stiffness/weakness
and involuntary movements. SB affects the development
of the spine and spinal cord before birth, and can result
in leg weakness and paralysis. There are three types of
SB: myelomeningocele, meningocele and SB occulta.
Both congenital and acquired mobility impairments
may necessitate the use of assistive technology to allevi-
ate impairments. Assistive technology refers to a wide
array of products and services which enhance function-
ing, participation and promote independence for people
who have disabilities. The Medicines and Healthcare
Products Regulatory Agency defines assistive technology
as any device “intended to compensate for or alleviate an
injury, handicap or illness or to replace a physical func-
tion” [3]. Assistive technology, such as wheelchairs, are
an “essential component for inclusive sustainable devel-
opment” [4], and can enhance the fundamental freedoms
and equality of opportunity for people with mobility im-
pairments and other disabilities. The United Nations
(UN) states that access to appropriate and affordable as-
sistive technology is a basic human right [5]; the UN
Convention on the Rights of Persons with Disabilities
has been ratified by 175 Member States, who are obli-
gated to ensure that affordable assistive technology is
available to all individuals in need. However, The World
Health Organization (WHO) estimates that only 10% of
people who need assistive technology have access to it
[6], and there remain persistent challenges in the equit-
able provision of assistive technology, particularly in de-
veloping countries. One of the keys issues is in assessing
the costs and benefits of different assistive technologies,
and developing evidence-based approaches to provision
which make best use of limited resources to maximise
the outcomes of people with disabilities.
The National Health Service (NHS) in the UK spends
almost £200million per year on wheelchairs alone [7],
thus there is an imperative to ensure that assistive mo-
bility technologies (AMTs) such as wheelchairs and
other mobility-enhancing interventions are provided in
an evidence-based manner, utilising evidence of cost-
effectiveness to guide service commissioning.
Economic evaluation and quality-adjusted life years
Methods of economic evaluation are now routinely em-
bedded in the evaluation of health technologies, and
used to estimate the cost of incremental benefits associ-
ated with new and alternative health interventions. Cost-
utility analysis, specifically estimation of cost per quality-
adjusted life years (QALYs), has become the predomin-
ant form of economic evaluation for new health tech-
nologies in the UK, in part due to the National Institute
for Health and Care Excellence’s (NICE) advocacy for
this approach [8]. The QALY framework has become in-
creasingly influential in health policy as a theoretically
universal and generic approach to measuring benefits via
a single common outcome.
In order to calculate QALYs, health state utility values
are needed. These values are most commonly derived
from preference-based measures (PBMs) of health-
related quality of life (HRQoL). HRQoL is a subjective
and multi-dimensional construct defined as the per-
ceived impact of health status on quality of life, includ-
ing physical, psychological and social functioning. PBMs
of HRQoL are used to assess the social desirability and
utility values associated with different states of health.
Bray et al. Health Economics Review            (2020) 10:9 Page 2 of 38
As the descriptive systems and value sets of generic
PBMs are usually derived from adult samples of the gen-
eral population, a common criticism is that their gener-
icity limits relevance and sensitivity in certain conditions
[9]. Moreover, in health states where quality of life takes
precedent over quantity of life (e.g. chronic illness, life-
limiting conditions and disability), QALYs derived from
generic PBMs can devalue the effectiveness of an inter-
vention [10].
Use of preference-based measures in the context of
mobility impairment
The accuracy of a QALY estimate is subject to the sensi-
tivity and applicability of the measurement tool used to
generate the utility data. PBMs have been found to be in-
consistent in both congenital and acquired mobility im-
pairments [11–13], furthermore different PBMs produce
significantly different results for AMT users [14, 15].
Previous research shows that patients with congenital
mobility impairments do not necessarily consider mobil-
ity to have a major impact on their HRQoL when suit-
able adaptations (such as AMT) are available [16, 17].
However, general population PBM value sets heavily im-
pact estimation of HRQoL when ability to walk is af-
fected. As an example, using the NICE approved UK
value set for the EuroQoL five-dimension (three level
version) (EQ-5D-3 L), the lowest possible mobility level
(‘confined to bed’) has a disutility of − 0.664, meaning
that an individual who is unable to walk but is otherwise
mobile using AMT can achieve a maximum utility value
of 0.336 (0 = death; 1 = perfect health), even if they have
no other HRQoL impacts. This raises the questions as to
whether existing PBMs are a valid source of utility values
in mobility impaired populations, particularly AMT
users.
The validity of PBMs can be tested by comparing re-
sults across groups of patients and by comparing generic
PBMs with condition-specific measures. For instance,
the EQ-5D-3 L and the Health Assessment Question-
naire (HAQ; an outcome measure for rheumatoid arth-
ritis) both measure health status in significantly different
ways [18], suggesting that the EQ-5D-3 L is lacking con-
sideration of important health impacts associated with
rheumatoid arthritis. These issues are partly due to the
insensitivity of the EQ-5D-3 L ‘mobility’ dimension to
accurately assess the varied impacts of rheumatoid arth-
ritis on mobility [19]. Similarly, the limited level choices
on the EQ-5D-3 L have been found to cause some indi-
viduals with mobility impairments to choose levels
which are more or less severe than their actual state,
such as using ‘I am confined to bed’ to substitute being
confined ‘to an electric wheelchair’ [20]. The updated
five level version of the EQ-5D (EQ-5D-5 L) is unlikely
to address this issue as the five level choices still focus
on walking and do not take account of alternative
methods of mobility.
Even simple generic measures of health status, such as
the single question self-reported health (SRH) scale (i.e.
“in general, would you say your health is excellent, very
good, good, fair, or poor?”), exhibit only limited correl-
ation with PBMs such as the Health Utilities Index
(HUI) 3 and Assessment of Quality of Life (AQoL) in
the context of SB [21] and CP [22]. Likewise, for individ-
uals with spinal cord injuries, the wording of the 36-
Item Short Form Health Survey (SF-36) (from which the
Short-Form Six-Dimension (SF-6D) PBM is calculated)
must be modified in order to maintain relevance [23].
Considering the potential issues of using generic PBMs
in disability, and congenital mobility impairment specif-
ically, it is apparent that there are a number of import-
ant considerations when using PBMs to evaluate AMT
interventions and other mobility-enhancing interven-
tions for people with congenital mobility impairments.
The objective of this systematic review is therefore to
examine the measurement properties of generic utility-
based PBMs in various forms of congenital mobility im-
pairment. All evidence reporting (or inferring) the valid-
ity, reliability and/or responsiveness of PBMs in
conditions associated with congenital mobility impair-
ment was collated and synthesised. Comparable
condition-specific reviews of PBM performance have
been conducted in mobility impairments such as
rheumatoid arthritis [24], CP [25] and multiple sclerosis
[26], however PBM performance has not been systemat-
ically summarised and collated across a range of con-
genital mobility impairments to date.
Methods
This systematic review followed the University of York
Centre for Reviews and Dissemination (CRD) principles
for conducting searches and extracting data [27]. Inter-
net reference database searching was the main strategy
for gathering evidence. Databases included: Cochrane
Collaboration Register and Library, Science Direct,
CINAHL, ASSIA, PsychINFO, PubMed and Web of Sci-
ence. Screening of reference lists, hand-searching and
targeted searching via the CRD database (which covers
the Database of Abstracts of Reviews of Effects (DARE),
the NHS Economic Evaluation Database (NHS EED) and
the Health Technology Association (HTA) database)
were carried out in addition to the primary database
searches. Due to limited translation resources, only stud-
ies written or translated into English or Welsh were eli-
gible for inclusion. Search results were managed using
the online bibliographic management software Refworks
(for storage of titles from the systematic searches) and
Mendeley (for referencing purposes). The systematic
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review protocol was registered on PROSPERO
(CRD42018088932).
Search terms
For the purpose of this review, mobility impairment was
defined as any congenital (i.e. present from or shortly after
birth) condition, impairment, disability or illness which
causes significant restrictions to mobility for 12months or
longer, and which necessitates the use of AMT, surgery or
rehabilitation to maintain, facilitate or substitute ambula-
tion, or to reduce complications related to mobility im-
pairment. Acquired mobility impairments (i.e. not present
from birth) and short-term injuries, such as sprains or
acute muscular injuries, were not included under this def-
inition of mobility impairment.
Search terms included a mixture of MeSH (Medical
Subject Heading) and non-MeSH words and phrases, di-
vided into two groups: ‘population’ and ‘outcomes’ (see
Table 1).
In order to identify studies referring to interventions ra-
ther than patient groups (e.g. studies examining ‘wheel-
chair users’ more generally), the ‘population’ search terms
also covered relevant AMTs and mobility-enhancing in-
terventions. The ‘outcomes’ search terms covered relevant
PBM keywords, including specific outcome measures
(such as the various versions of the EQ-5D and HUI mea-
sures). An NHS posture and mobility service manager was
consulted to refine the search terms. An example of a
search string is shown in Table 2.
Study eligibility
Any study reporting the performance of PBMs of
HRQoL in patient groups with congenital mobility im-
pairments was eligible for inclusion. This included stud-
ies reporting proxy outcomes. There was no restriction
on study type. Studies focussing solely on non-PBMs of
HRQoL or acquired mobility impairments were ex-
cluded. Studies which included patient groups with vary-
ing degrees of disability/disease severity were considered
for inclusion if the majority of patients had a congenital
mobility impairment or if the data for patients with con-
genital mobility impairments was reported separately
(i.e. sub-group analysis).
Screening
Two researchers undertook each stage of the screening
process. For the initial screening process, all identified
studies were assessed for relevance based on their title
and descriptor terms, the remaining studies were then
assessed by their abstract. All studies considered relevant
after the initial screening process were then obtained in
full. Both reviewers screened each study independently.
A third researcher was consulted when there was dis-
agreement about the inclusion of a specific study.
Quality appraisal
All relevant studies which met the initial inclusion cri-
teria were critically appraised for methodological quality
by two researchers. Quality appraisal methods were
adapted from similar systematic reviews in other clinical
areas [28–30]. Quality appraisal was not used to exclude
studies, but to illustrate the overall quality of research
conducted in this topic area. Quality appraisal focussed
on six key areas:
 Whether tests of statistical significance were carried
out
 Differences between interventions and/or patient
groups (i.e. sub-group analysis)
 Clinical significance and relevance of results
 Reporting of missing data
 Response and completion rates
 Explicit reporting of inclusion/exclusion criteria
Data extraction
Data extraction criteria included:
 Study characteristics: study type, country, number/
composition of study groups, missing data
 Demographics: number of participants, age, gender,
type/severity of mobility impairment
 Measures: Generic PBMs used, condition-specific
measures used, other clinically relevant measures
used
 Outcomes: Mean utility scores, mean utility scores
for relevant sub-groups, statistical significance
between groups
 Performance: Known group analyses, convergent
validity (correlation between outcomes and/or
respondent types), responsiveness, reliability,
response/completion rates
Analysis of the performance of preference-based
measures
PBM performance indicators were adapted from COS-
MIN measurement property guidance for health-related
patient-reported outcomes [31].
Assessment of validity
In this context validity refers to the extent to which a
PBM can be considered to measure what it has been de-
signed to measure (i.e. HRQoL), and whether it does so
in a systematic manner. By establishing whether a spe-
cific PBM is sufficiently valid in a particular patient
group, greater confidence can be placed in the generated
data. We focussed predominantly on construct validity
in this review.
Construct validity was assessed in a number of ways.
Firstly, known-group analyses were used to assess
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whether specific PBMs were able to detect expected dif-
ferences between different patient groups (i.e. variance
due to severity of illness). Secondly, convergent validity
was determined by examining correlation between com-
parable outcomes, for instance between PBMs and
condition-specific measures with comparable constructs.
Finally, convergent validity was further examined by
looking at correlation between respondents types (i.e.
self-reported and proxy utility outcomes). In the interest
of uniformity, the strength of correlations was defined as
absent (r < 0.20), weak (r = 0.20 to 0.35), moderate (r =
0.35 to 0.50) and strong (r ≥ 0.50) [32].
Assessment of reliability
Reliability refers to the replicability of results. Reliability
is commonly assessed by examining test-retest results
and inter-rater reliability of PBMs in defined unchanging
patient groups.
Table 1 Search terms and phrases
Population Outcomes
Assisted mobility Mobility scooter 15D
Assistive mobility Mobility technolog* AQoL
Brain damage* Motor dis* Assessment of Quality of Life
Brain injur* Motorised scooter Child health utilities
Buggy Neurodisability Child health utility
Caliper Neurological dis* CHU9D
Cane Neuromotor dis* CHU-9D
Cerebral palsy Neuromuscular dis* EQ 5D
Club foot Orthoti* EQ-5D
Clubfoot Osteogenesis imperfecta EuroQoL
Crutch* Paraly* Health utilities
Diplegi* Paraplegi* Health-utilities
Dysmelia Physical disab* HUI
Dystroph* Physical impair* HUI2
Electric chair Physically disab* HUI3
Electric powered indoor outdoor chair Physically impaired Preference based
Electric powered indoor/outdoor chair Power chair Preference-based
Electric scooter Powered chair QALY
Electrically powered indoor outdoor chair Pushchair Quality adjusted life year
Electrically powered indoor/outdoor chair Quadriplegi* Quality-adjusted life year
Electronically powered indoor outdoor chair Rollator Quality of well-being scale
Electronically powered indoor/outdoor chair Scooter QWB-SA
*encephal* Spina bifida Short Form Six Dimension
EPIOC Spinal muscular atrophy Short From 6 Dimension





Knee walker Walking aid
Mobility aid Walking frame
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Assessment of responsiveness
Responsiveness refers to the extent to which a measure
can identify changes in health status [28]. A responsive
measure should be able to detect clinically significant
changes in health outcomes over time [29]. Responsive-
ness was determined by examining the relationship be-
tween outcomes derived from PBMs and other relevant
measures, before and after an intervention.
Evidence synthesis
Descriptive synthesis of search results was conducted
[27] and presented in tabulated form. Narrative synthesis
was undertaken to develop a structured narrative of re-
sults; extracted results were grouped by type of mobility
impairment and category of PBM performance.
Results
See Fig. 1 for search outcomes and the screening process
flowchart. Searches were conducted from March to May
2018. In total 1489 study articles were identified: 1332
from the bibliographic searches and 157 articles from
other sources (i.e. CRD database, screening of reference
lists and hand-searching), of which 410 duplicates were
removed. After screening of titles and abstracts, 66
Table 2 Example of keyword search string
(“Assisted mobility” Or “Assistive mobility” Or “Brain damage*” Or “Brain
injur*” Or Buggy Or Caliper Or Cane Or “Cerebral palsy” Or “Club foot”
Or Clubfoot Or Crutch* Or Diplegi* Or Dysmelia Or Dystroph* Or
“Electric chair” Or “Electric powered indoor outdoor chair” Or “Electric
powered indoor/outdoor chair” Or “Electric scooter” Or “Electrically
powered indoor outdoor chair” Or “Electrically powered indoor/outdoor
chair” Or “Electronically powered indoor outdoor chair” Or “Electronically
powered indoor/outdoor chair” Or encephal* Or EPIOC Or “Functional
disab*” Or Handicap* Or Hemiplegi* Or Hydrocephalus Or “Knee
scooter” Or “Knee walker” Or “Mobility aid” Or “Mobility device” Or
“Mobility dis*” Or “Mobility equipment” Or “Mobility impair*” Or “Mobility
scooter” Or “Mobility technolog*” Or “Motor dis*” Or “Motorised scooter”
Or Neurodisability Or “Neurological dis*” Or “Neuromotor dis*” Or
“Neuromuscular dis*” Or Orthoti* Or “Osteogenesis imperfect” Or Paraly*
Or Paraplegi* Or “Physical disab*” Or “Physical impair*” Or “Physically
disab*” Or “Physically impaired” Or “Power chair” Or “Powered chair” Or
Pushchair Or Quadriplegi* Or Rollator Or Scooter Or “Spina bifida” Or
“Spinal muscular atrophy” Or Talipes Or Tetraplegi* Or “Walk aid” Or
“Walk-aid” Or Walker Or “Walking aid” Or “Walking frame” Or “Walking
stick” Or “Walking-aid” Or Wheelchair) AND (15D OR AQoL OR
“Assessment of Quality of Life” OR “Child health utilities” OR “Child
health utility” OR CHU9D OR “CHU-9D” OR EQ. 5D OR “EQ-5D” OR
EuroQoL OR “Health utilities” OR “Health-utilities” OR HUI OR HUI2 OR
HUI3 OR “Preference-based” OR “Preference based” OR QALY OR “Quality
adjusted life year” OR “Quality of well-being scale” OR “Quality-adjusted
life year” OR “QWB-SA” OR “Short Form Six Dimension” OR “Short From 6
Dimension” OR SF6D OR “SF-6D”)
Fig. 1 PRISMA flowchart for search outcomes and screening process
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studies were identified as potentially eligible. Following
full review of full-texts, 35 studies were excluded for a
variety of reasons (see Fig. 1). In total 31 studies were
identified as relevant and eligible for inclusion in the sys-
tematic review. Quality appraisal outcomes are presented
in Table 3.
Study and patient characteristics
Study and participant characteristics are presented in
Table 4. Most of the studies (22 of 31) were cross-
sectional studies [15, 21, 22, 34, 36–38, 40–45, 47–52,
54, 58, 59], six were prospective cohort studies [33, 35,
39, 46, 53, 57], two were case-control studies [11, 56]
and one was a randomised controlled trial [55]. The se-
lected studies were conducted in a range of different
countries; most were (n = 15) from Canada [21, 22, 33,
35, 36, 38–43, 46, 49, 53, 57]. The sample sizes of rele-
vant study groups ranged from 13 [15] to 770 [44].
Fourteen studies included data relating to CP [22, 33,
35, 36, 39, 46, 48–51, 53, 55, 57, 58], six included data
relating to SB [21, 38, 51, 52, 54, 56] and five included
data relating to childhood hydrocephalus [40–43, 45].
Data for a range of other relevant conditions were also
found in either single studies or from extractable sub-
groups, these included muscular dystrophy [34, 44],
spinal muscular atrophy [47], Morquio A syndrome [37],
congenital clubfoot [59] and microcephaly [51]. Three
studies focused on multiple conditions where sub-group
data could not be examined separately [11, 15, 51].
The vast majority of studies (23 of 31) included only
child/adolescent participants [11, 15, 33, 35, 36, 38–44,
46–54, 56, 58]. Of the remaining studies, six included
children/adolescents and adults [21, 22, 34, 37, 55, 57]
and two included only adults [45, 59]. PBM reporting
was predominantly from proxies (13 of 23 studies);
eleven studies included both self-reported and proxy
data [15, 21, 22, 36, 43, 48–50, 53, 54, 57] and seven
studies included only self-reported PBM data [11, 34, 37,
45, 55, 58, 59].
In terms of use of PBMs, 22 of the studies used a ver-
sion of the HUI [15, 21, 22, 33, 35, 36, 38–44, 46, 48, 49,
51–54, 56, 57], eight used a version of the EQ-5D [11,
15, 34, 37, 47, 50, 58, 59], three used a version of AQoL
instrument [21, 22, 57], one used the 15D [45] and one
used the SF-6D [55].
Narrative synthesis
Utility outcomes are presented in Table 5 and PBM per-
formance outcomes are presented in Table 6. The narra-
tive synthesis is categorised by type of mobility
impairment and PBM performance indicator. No studies
reported PBM reliability outcomes, therefore reliability
results have not been presented.
Cerebral palsy
Known-group analyses
Five studies reported known-group analyses in CP [22,
33, 51, 53, 58]. Petrou and Kupek [51] estimated that the
adjusted HUI3 disutility of childhood CP from perfect
health was − 0.72 (95% confidence interval [CI] -0.61 to
− 0.85), and − 0.65 (95% CI − 0.54 to − 0.78) from child-
hood norms. Two studies found that as CP severity (i.e.
gross motor function) increased, average utility scores
(measured using HUI3 or AQoL) decreased in adoles-
cents and young adults with CP [22, 53]; Rosenbaum
et al. [53] found statistically significant differences in
mean utility scores between most Gross Motor Function
Classification System (GMFCS) levels (p < 0.01). One
study demonstrated that the vision, pain and cognition
dimensions of the HUI3 steadily declined as GMFCS
level increased, however statistical significance was not
reported [33]. Vitale et al. [58] found that adolescents
with CP had significantly higher average EQ-5D utility
scores (0.92) compared to adolescents with scoliosis
(with comorbidities) (0.73; p > 0.05), although selection
of these patient sub-groups was not explicitly justified
and the version of the EQ-5D was not reported.
Convergent validity: comparing measures
Two studies reported that GMFCS level was correlated
with worsening utility scores [22, 53]. Young et al. [22]
found that GMFCS level in childhood was responsible
for between 45% (AQoL: β = − 0.148; p < 0.001) and 53%
(HUI3: β = − 0.205; p < 0.001) of variance in utility
scores. Rosenbaum et al. [53] found a strong negative
correlation between the HUI3 utility scores of adoles-
cents with CP and their GMFCS level (r = − 0.81). In
terms of individual PBM dimensions, results from four
studies were varied [33, 35, 39, 49]; Kennes et al. [39]
found that the dimension most associated with GMFCS
level in children was ambulation (tau-b = 0.82; p < 0.01).
Bartlett et al. [33] found that the HUI3 vision, pain and
cognition dimensions generally worsened as GMFCS
level increased in adolescents; however, there was no in-
dication that these dimensions were determinants of
motor capacity decline. Two studies [35, 49] reported a
significant negative association between the HUI3 pain
dimension and GMFCS level in children with CP, how-
ever both of these studies only examined the HUI3 pain
dimension and not the full HUI3 system.
Three studies reported various levels of correlation be-
tween PBMs and other outcome measures in CP [22, 46,
53]. Young et al. [22] found moderate correlation be-
tween utility score and SRH (r = 0.41; p < 0.001 for both
the HUI3 and AQoL). Two studies compared the Qual-
ity of Life Instrument for People with Developmental
Disabilities (QOL Instrument) and the HUI3 [46, 53];
Rosenbaum et al. [53] reported that adolescents’ HUI3
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utility scores explained between 3% (belonging) and 14%
(being) of variance in QOL Instrument dimension
scores, while Livingston and Rosenbaum [46] reported
that the HUI3 and QOL Instrument shared up to 23%
variance, thus the relationship between the measures
was considered to be moderate at best.
Two studies reported on the relationship between
different PBMs in CP [22, 57]. Although utility scores
derived from the HUI3 and AQoL were strongly cor-
related (r = 0.87; p < 0.001) [22], HUI3 derived utility
scores tended to be lower than AQoL derived utility
scores [22, 57].
Convergent validity: comparing respondents
Four studies examined correlation between respondents
in CP [22, 48–50]. Morrow et al. [48] reported moderate
agreement between parents and doctors of children with
CP for the HUI2/3 dimensions of sensation (63.6%
agreement; Kappa 0.41), cognition (70% agreement;
Kappa 0.56), self-care (100% agreement; Kappa 1.00) and
ambulation (63.6% agreement; Kappa 0.46). Good correl-
ation was also found between child self-reported HUI3
pain scores and equivalent parent proxy scores (Good-
man and Kruskal’s y statistic = 0.57; p < 0.001) [49].
Perez Sousa et al. [50] reported a high level of dis-
agreement between parents and children on the EQ-5D
Table 3 Quality appraisal outcomes


















Bartlett et al. (2010) [33] Y Y Y Y X Y
Bray et al. (2017) [15] Y Y Y Y Y Y
Burstrom et al. (2014) [11] Y Y X Y Y X
Cavazza et al. 2016 [34] X X X X X X
Christensen et al. (2016) [35] Y Y Y X Y X
Findlay et al. (2015) [36] Y Y Y Y Y X
Hendriksz etl al (2014) [37]. Y Y Y Y X Y
Karmur and Kulkarni (2018) [38] Y X Y Y X X
Kennes et al. (2002) [39] Y Y Y Y X Y
Kulkarni et al. (2004) [40] Y X Y X Y Y
Kulkarni (2006) [41] Y Y X Y X Y
Kulkarni et al. (2008) [42] Y X Y Y Y X
Kulkarni et al. (2008) [43] Y Y Y X Y Y
Landfeldt et al. (2016) [44] Y X Y X Y X
Lindquist et al. (2014) [45] Y Y Y X X Y
Livingston and Rosenbaum (2008) [46] Y X Y Y X X
Lopez-Bastida et al. (2017) [47] X X Y Y X X
Morrow et al. (2011) [48]. Y Y Y X Y Y
Penner et al. (2013) [49] Y Y Y X Y X
Perez Sousa et al. (2017) [50] Y Y Y Y Y Y
Petrou and Kupec (2009) [51] Y Y Y Y X Y
Rocque et al. (2015) [52] Y Y Y X X Y
Rosenbaum et al. (2007) [53] Y Y Y Y X Y
Sims-Williams et al. (2016) [54] Y Y Y Y X Y
Slaman et al. (2015) [55] Y X Y X X Y
Tilford et al. (2005) [56] Y X Y X Y X
Usuba et al. (2014) [57] Y Y Y Y Y Y
Vitale et al. (2001) [58] Y Y Y X X Y
Wallander et al. (2009) [59]. Y X Y X Y Y
Young et al. (2010) [22]. Y Y Y Y Y Y
Young et al. (2013) [21] Y Y Y X Y Y
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youth version (EQ-5D-Y); parents reported a lower fre-
quency of problems on all EQ-5D-Y proxy dimensions,
particularly fathers.
Responsiveness
Five studies allowed analysis of PBM responsiveness in
CP [33, 35, 46, 55, 57]. Adolescents with a GMFCS level
of V exhibited the largest decreases in HUI3 dimension
levels over time, compared to adolescents with GMFCS
levels of III and IV [33]. Christensen et al. [35] reported
a significant association between physicians’ primary
pain aetiology and change in HUI3 pain status (p =
0.001). Conversely, in two studies utility outcomes did
not change significantly over time; HUI3 utility out-
comes were found to be stable over a 1 year period for
adolescents with CP (G = 0.91) [46], likewise utility out-
comes (derived from HUI3 and AQoL) did not signifi-
cantly change over an 8 year follow-up period [57].
Slaman et al. [55] utilised the SF-6D in a randomised
controlled trial, but did not find a significant difference
between the control and intervention groups at the end
of the trial (p = 0.42).
Spina bifida
Known-group analyses
Three studies reported known-group analyses in SB [51,
52, 56], two of which found that clinical factors had a
significant impact on utility scores. Petrou and Kupek
[51] estimated that the adjusted HUI3 disutility of child-
hood SB from perfect health was − 0.55 (95% CI − 0.40
to − 0.70), and − 0.48 (95% CI − 0.33 to − 0.63) from
childhood norms. A statistically significant effect of SB
diagnosis on HUI3 utility score (p < 0.001) was reported
[52]; children diagnosed with myelomeningocele (mean
utility score = 0.51) tended to have lower utility scores
compared to children with closed dysraphism (mean
utility score = 0.77). Tilford et al. [56] reported that le-
sion location in childhood SB had a significant impact
on overall utility (p < 0.01); individuals with sacral le-
sions had the highest overall mean utility (0.61; ±0.26).
Two studies reported correlation between clinical fac-
tors and utility scores in SB [21, 38]. Anatomical myelo-
meningocele level was found to have a significant effect
on the HUI utility scores of children with myelomenin-
gocele and shunted hydrocephalus (mean HUI score =
0.03; 95% CI 0.01 to 0.05; p = 0.01) [38], with lower mye-
lomeningocele level showing association with higher
utility scores. A similar trend was reported by Young
et al. [21], who found that the most important single fac-
tor contributing to utility outcomes in SB was surgical
lesion level, which was responsible for between 18%
(AQoL) and 40% (HUI3) of variance in utility scores.
Convergent validity: comparing measures
Two studies reported various levels of correlation between
PBMs and other outcome measures in SB [21, 54]. Child
self-reported HUI3 utility scores were not found to be
highly correlated with VAS scores (r = 0.488) [54]. Like-
wise, the SRH was only moderately correlated with utility
scores in SB (HUI3: r = − 0.45; p < 0.001 / AQoL: r = −
0.58; p < 0.001) [21]. Only the HAQ was found to be
strongly correlated with utility score (HUI3: r = 0.79; p <
0.001 / AQoL: r = 0.70; p < 0.001) [21].
Young et al. [21] compared results from different
PBMs in SB, and found that mean utility scores on the
AQoL were lower than mean utility scores on the HUI3
for all sub-groups, despite strong correlation between
these measures (r = 0.73; p < 0.001).
Convergent validity: comparing respondents
Sims-Williams et al. [54] reported that proxy and self-
reported HUI3 utility scores were highly correlated for
children with SB (r = 0.85; significance not reported).
Young et al. [21] found that mean self-reported utility
scores were slightly higher than equivalent proxy scores
(HUI3 mean + 0.04; AQoL mean + 0.03) however re-
spondent type was not influential in their regression
analysis.
PBM responsiveness outcomes in SB were not found
in the literature.
Mixed patient groups and mobility impairments
This section includes results from studies which did not
focus on specific conditions, and where sub-group data
could not be examined separately. Relevant conditions/
mobility impairments included muscular dystrophy,
spinal muscular atrophy, CP, SB, orthopaedic lower limb
deformities, artrogryposis multiple congenital, achondro-
plasia and hemiplegia.
Known-group analyses
Two studies reported known-group analyses in studies of
mixed patient groups [11, 51]. Petrou and Kupek [51]
found that children with muscular dystrophy or spinal
muscular atrophy had a mean utility score of 0.39, equat-
ing to an adjusted disutility from perfect health of − 0.62
(95% CI − 0.471 to − 0.761), and an adjusted disutility
from childhood norms of − 0.54 (95% CI − 0.400 to −
0.690). Burstrom et al. [11] reported that children with a
functional disability (64% congenital; see Table 4 for pa-
tient characteristics) had significantly lower EQ-5D-Y di-
mension scores than the general population (p < 0.001).
Convergent validity: comparing outcomes
Moderate correlation was found between the individual
dimensions of the EQ-5D-Y and the dimensions of other
measures (KIDSCREEN-27 and KIDSCREEN-10) and
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the life satisfaction ladder (LSL), when completed by
children with functional disabilities [11] . The EQ-5D-Y
anxiety/depression dimension exhibited significant cor-
relation with the KIDSCREEN-27 psychological well-
being dimension (r = − 0.51; p = 0.001), the
KIDSCREEN-27 physical well-being dimension (r = −
0.53; p = 0.001), and the LSL (r = − 0.54; p < 0.001) [11].
Large variance was observed between utility scores de-
rived from different PBMs for young wheelchair users;
mean utility scores ranged from 0.24 (EQ-5D-Y) to 0.53
(HUI2) for self-reporting children, and from 0.01 (EQ-
5D-Y) to 0.49 (HUI2) for parent proxies [15].
Convergent validity: comparing respondents
A significant strong correlation was observed between
dyads of young wheelchair users (84.6% children with
CP, see Table 4 for patient characteristics) and parent
proxies for a number of utility measures: EQ-5D-Y (r =
0.67; p = 0.026), HUI2 (r = 0.73; p = 0.005) and HUI3
(r = 0.84; p < 0.001) [15]. Using Bland-Altman plots [60],
sufficient agreement was observed between dyads for the
HUI2 (CL = 0.22) and HUI3 (CL = 0.22), but not the EQ-
5D-Y (CL = 1.04). A significant respondent type effect
was found for all measures, with child self-reported util-
ity scores significantly higher for the EQ-5D-Y (p =
0.012), HUI2 (p = 0.021) and HUI3 (p = 0.009) than
equivalent proxy measures [15].
PBM responsiveness outcomes were not found in the
literature for this patient group.
Childhood hydrocephalus (mixed aetiology)
Known-group analyses
Lindquist et al. [45] found that adults with a history of
hydrocephalus (with or without neuro-impairment) had
significantly lower 15D dimension scores, compared to a
control group, in the dimensions of vision (p = 0.001),
eating (p = 0.000), usual activities (p = 0.004) and mental
function (p = 0.000).
Convergent validity: comparing measures
Four studies examined the relationship between the
Hydrocephalus Outcome Questionnaire (HOQ) and
PBMs [40–43], however only three of these studies per-
formed relevant statistical analyses [40, 41, 43]. Kulkarni
[41] reported strong correlation (0.81) and a strong lin-
ear relationship between HUI2 utility score and HOQ
outcomes for children with hydrocephalus. Simple and
complex linear regression models both accounted for a
large proportion of HUI2 variability (adjusted R2 = 0.66
and 0.80 respectively). Similarly, a strong correlation was
found between HUI2 utility score and the HOQ scores
for overall health (r = 0.81), physical health (r = 0.88),
social-emotional (r = 0.56) and cognitive (r = 0.57) [40].
Furthermore, a significant positive correlation was
exhibited between self-reported scores on the child-
completed version of the HOQ (cHOQ) and proxy-
reported utility scores on the HUI3 (r = 0.60; p < 0.001)
[43].
PBM responsiveness outcomes in childhood hydro-
cephalus were not found in the literature.
Other conditions and mobility impairments
Only known-group analyses were reported for the fol-
lowing conditions associated with mobility impairment:
Muscular dystrophy
Landfeldt et al. [44] reported that ambulatory status and
age were significantly associated with HUI utility scores
in muscular dystrophy (HUI version not stated; p <
0.001); young ambulators (5–7 years old) had the highest
utility scores on average (0.75), whilst older non-
ambulators (≥16 years old) had the lowest utility scores
on average (0.15).
Spinal muscular atrophy
Lopez-Bastida et al. [47] reported that children with Type
II spinal muscular atrophy tended to have lower mean
proxy utility scores (− 0.01; ±0.35) than the combined
average for all forms of spinal muscular atrophy (0.16; ±
0.44), however statistical analysis was not undertaken.
Morquio A syndrome
One study found that for both adults and children with
Morquio A syndrome, wheelchair use was significantly
associated with lower utility scores [37]. Significant dif-
ferences were reported in the adult group between non-
wheelchair users and occasional wheelchair users (p =
0.0115) and between occasional wheelchair users and
full-time wheelchair users (p = 0.0007). In the child
group significant differences were reported between
non-wheelchair users and full-time wheelchair users
(p = 0.0018) and occasional wheelchair users and full-
time wheelchair users (p = 0.0007).
Congenital clubfoot
Wallander et al. [59] found that male adult patients with
congenital clubfoot (CCF) had significantly better overall
utility scores than the male norm group (p = 0.027). The
female CCF group had a lower average utility score than
the norm group, but not significantly (significance level
not reported).
Microcephaly
Petrou and Kupek [51] found that children with micro-
cephaly had a mean utility score of 0.14, equating to an
adjusted disutility from perfect health of − 0.82 (95% CI
− 0.67 to − 0.97), and an adjusted disutility from child-
hood norms of − 0.75 (95% CI − 0.60 to − 0.90).
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Discussion
The results from this systematic review demonstrate that
PBMs have been used in a relatively small number of
studies relating to congenital mobility impairments. In
conditions such as CP and SB, increased clinical severity
appears to be associated with decreased utility. This is
particularly evident using the HUI3, which was also the
most commonly used PBM found in this review. In par-
ticular, there appears to be a relationship between utility
outcomes and GMFCS level in CP, and clinical factors
such as lesion level in SB. In case-control studies, utility
outcomes tended to be significantly lower in the case
groups, although it is worth noting that in one study the
male case-group had significantly higher utility out-
comes compared to the control [59].
In order to demonstrate sufficient applicability and
sensitivity in a specific disease or disability, association
between PBMs and validated clinical/condition-specific
outcomes is of key importance. In this respect existing
PBMs show weakness in various conditions associated
with congenital mobility impairments; exhibiting gener-
ally limited correlation with measures such as the QOL
Instrument, VAS, SRH, KIDSCREEN-27, KIDSCREEN-
10 and LSL. Only the GMFCS and HOQ/cHOQ ap-
peared to be well correlated with PBMs across a number
of studies, although it is important to note that GMFCS
is a classification system of gross motor function and
not an outcome measure.
The results from this systematic review highlight im-
portant considerations for the use of PBMs in health
states associated with congenital mobility impairment. It
is first of note that the use of PBMs has been dominated
by studies in CP, followed by SB. This is somewhat un-
surprising given that these are two of the most prevalent
congenital disabilities which affect mobility. Secondly, it
is important to acknowledge that only two studies fo-
cussed on adults alone, and that both of these studies
were measuring utility outcomes in adults following con-
ditions experienced in childhood [45, 59]. This focus on
children and adolescents is again unsurprising, as many
congenital conditions can be life-limiting, thus examin-
ing health outcomes at a young age becomes particularly
important. However, this also shows a lack of focus on
the health outcomes of adults who have life-long experi-
ence of mobility impairment, and the potential ways in
which their health outcomes could change over time or
be improved.
There is some evidence to demonstrate that different
PBMs vary in their estimation of utility outcomes in
states of impaired mobility. For instance, Bray et al. [15]
found large variation between the EQ-5D-Y and HUI2/3
utility scores for wheelchair users. Likewise, Usuba et al.
[57] and Young et al. [21, 22] found that utility out-
comes were generally higher when derived from the
AQoL than the HUI3 for individuals with CP, but vice
versa for individuals with SB. This is despite the strong
correlation between the AQoL and HUI3 in these popu-
lations [21, 22]. Unfortunately, statistical differences be-
tween these measures were not reported, but it is still
important to consider the implications that these differ-
ences could have on subsequent QALY outcomes. For
instance, if one PBM were to produce significantly
higher utility scores than another, this would mean sig-
nificantly different estimates of cost per QALYs and thus
estimates of cost-effectiveness. At present there is lim-
ited evidence to enable health economists and re-
searchers to choose between these different PBMs for
use in congenital mobility impairments.
Despite documented limitations [61], QALYs have be-
come increasingly influential in health policy as a means
to determine the cost-effectiveness of new treatments and
services, and therefore guide healthcare funding and pri-
oritisation decisions. It is therefore imperative that the
PBMs used to develop QALYs are accurate. Otherwise,
the cost-effectiveness of certain interventions in certain
patient groups could be underestimated. This in turn
could impact funding and prioritisation decisions. In the
context of congenital mobility impairment, this could im-
pact the provision of AMT and other mobility-enhancing
interventions, and subsequently impact patient outcomes.
This is particularly important considering the ongoing is-
sues of unmet need in assistive technology provision. The
WHO Priority Assistive Products List (APL) was launched
in 2016 to help tackle unmet need [62]. The APL contains
50 priority assistive technology products, and was pro-
duced through consultation with users, experts and other
key stakeholders. Appropriate PBM data, and subsequent
estimates of cost-effectiveness, could help to inform the
APL and ensure that the most effective and cost-effective
AMTs are prioritised.
Considering that the majority of evidence found in this
review related to children, the relationship between self-
reported and proxy utility outcomes is particularly sig-
nificant. The results from various studies in this review
demonstrate that proxy-reporting of utility is consist-
ently different to that of self-reporters, including signifi-
cant respondent-type effects and limited agreement
between respondents. Interestingly, proxy respondents
were found to both underestimate and overestimate util-
ity outcomes compared to self-reporters. It is therefore
important to prioritise outcome measurement from the
patient, although this can be challenging in populations
who may lack capacity, such as young children and indi-
viduals with cognitive impairments.
Methodological implications
Due to the underlying trade-off between quantity and
quality of life in the calculation of utility values and
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subsequent QALYs, there is a tendency for lower value
to be placed on extending the length of life of people
with long-term disabilities [10, 63], as their quality of life
is routinely considered to be worse than that of an able-
bodied person. Thus, when using the QALY framework
to assess the outcomes of individuals with disabilities, it
is difficult to achieve substantially higher quality of life
when compared to individuals without disabilities, rais-
ing concerns about bias [10]. To some extent these is-
sues could be a result of using generic PBMs to value
disabled health states.
One of the underlying issues of using PBMs in disabil-
ity is that the definition of HRQoL differs profoundly be-
tween people with disabilities and the general public
[64]. When asked to define HRQoL, young wheelchair
users focus on a number of concepts not explicitly mea-
sured using generic PBMs, such as ability to adapt,
achievement and independence [17]. The experience of
disability also affects HRQoL perceptions. Mechanisms
of adaptation, coping and adjustment can help individ-
uals with disabilities to experience diminishing effects to
their HRQoL over time. These processes are also influ-
enced by the onset of disability, as individuals with con-
genital disabilities demonstrate better adaptation than
individuals with acquired disabilities [2]. The evaluation
of states of disability by non-disabled individuals may
therefore cause such states to have an exaggerated per-
ceived impact on HRQoL and health status [65], particu-
larly with regards to congenital disability.
When assessing the desirability of hypothetical health
states, individuals focus on the transition from their own
health state to the hypothetical health state, thus general
public beliefs about the impact of disability do not al-
ways reflect the lived experience [66, 67]. Focus on per-
sonal transition means that processes such as adaptation
are not accounted for, causing a discrepancy in how
states of disability impact HRQoL [9].
An alternative approach is to use more sensitive
condition-specific measures to model utility values on
generic PBMs. Although this approach is advocated by
NICE [68] there are serious concerns about the validity
of modelled utility values [69], as it cannot be assumed
that modelled utility values are representative of directly
measured utility values [70]. Using modelled utility data
to guide funding and resource allocation decisions is
therefore controversial. For instance, Sidovar et al. [71]
mapped the 12-Item Multiple Sclerosis Walking Scale
(MSWS-12) onto the EQ-5D-3 L. While prediction esti-
mates were relatively precise for patients with moder-
ately impaired mobility, they were significantly less
accurate for individuals with severe impairments.
Neilson et al. [72] suggest supplementing PBMs with
additional questions relating to functional activities
which have a large impact on overall quality of life, such
as ‘sitting’ for AMT users. For instance, Persson et al.
[73] added complimentary mobility and social relation-
ship items to the EQ-5D-3 L to increase sensitivity in
disabled populations. However, this approach assumes
that supplemental questions can be mapped on to the
health state preference values of existing measures with-
out impacting accuracy.
Limitations and challenges
Defining the term congenital mobility impairment was
one of the key challenges of designing this systematic re-
view. An NHS posture and mobility service manager was
consulted to help construct the search terms, and a
number of preliminary searches were carried out to test
search terms for both sensitivity and scope. A multitude
of conditions and disabilities can affect mobility from
birth or early infancy, thus we attempted to cover a wide
variety of these in our search terms, but accept that
there are likely to be conditions and disabilities which
were missed. Given the search results, we are confident
that we have captured the vast majority of relevant stud-
ies relating to at least the most common forms of con-
genital mobility impairment. One key issue was
considering whether to include studies relating to hydro-
cephalus in this review. Although hydrocephalus is not
always associated with mobility impairment, it can cause
movement issues and is commonly related to relevant
conditions such as CP and SB. We therefore chose to in-
clude studies related to childhood hydrocephalus.
We chose specifically to focus on congenital mobility
impairment due to the significant differences in life sat-
isfaction, self-identity and self-efficacy experienced by
people with congenital disabilities compared to people
with acquired disabilities [2]. Further research could
compare PBM performance in congenital and acquired
mobility impairments. Previous reviews have reported
mixed results regarding the validity and responsiveness
of existing PBMs in the assessment of health states asso-
ciated with acquired mobility impairments, such as
rheumatoid arthritis [24] and multiple sclerosis [26].
Conclusion
To our knowledge, this is the first systematic review of
the use of PBMs in congenital mobility impairment. Evi-
dence suggests that existing generic PBMs exhibit im-
portant issues relating to validity and responsiveness,
and thus care must be taken when selecting a PBM as
an outcome measure in this context. Condition or dis-
ability specific approaches to utility measurement, such
as the mobility and quality of life (MobQoL) outcome
measure [74], could improve the sensitivity and applic-
ability of utility measurement in this context.
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